Generate Biomedicines, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-02-04. It has amended it 2 times. It filed its final prospectus on 2026-02-27, at a public offering price of $16.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock has been approved for listing on The Nasdaq Global Select Market (“Nasdaq”) under the symbol “GENB.”From the 424B4 filed 2026-02-27
Shares offered
This is the initial public offering of shares of common stock of Generate Biomedicines, Inc. We are offering 25,000,000 shares of our common stock.From the 424B4 filed 2026-02-27
Offering price
The initial public offering price per share is $16.00.From the 424B4 filed 2026-02-27
Use of proceeds
We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, primarily to (i) advance GB-0895 through the completion of our two Phase 3 trials in severe asthma, (ii) complete our ongoing Phase 1b clinical trial of GB-0895 for the treatment of COPD and to initiate the next phase of clinical development (pending results from our Phase 1b trial in COPD and regulatory alignment), (iii) fund platform and technology innovation and engineer multiple programs and product candidates through development candidate nomination and into IND-enabling activities and (iv) advance GB-4362 and GB-5267 through topline Phase 1…From the 424B4 filed 2026-02-27
Net loss or income
We have incurred recurring losses since inception, including a net loss of $223.0 million and $181.4 million for the years ended December 31, 2025 and December 31, 2024, respectively.From the S-1/A filed 2026-02-23
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-02-04 | Registration statement filed | S-1 |
| 2026-02-13 | Registration statement amended | S-1/A |
| 2026-02-23 | Registration statement amended | S-1/A |
| 2026-02-27 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Generate Biomedicines, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.